Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review found that 5α-reductase inhibitors (such as finasteride and dutasteride) effectively reduce prostate size and stabilize hair loss but are associated with sexual dysfunction; they remain essential treatments for BPH and androgenic alopecia, requiring tailored risk-benefit assessments.

This study reviews the psychological side effects of finasteride, noting a potential association between 5-AR inhibitors and increased depressive symptoms, but emphasizes that the causal link to suicidal ideation remains unclear; the authors recommend mental health screenings and close monitoring for patients starting this medication.

This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.

Over 40% of postmenopausal women experience hair loss, with treatments aiming to stop further loss and possibly thicken hair.

This study reports that perioperative use of dutasteride, both orally and through mesotherapy, may enhance hair graft survival and reduce shock loss in patients undergoing hair transplantation for androgenetic alopecia.

This review discusses adverse effects of 5 alpha-reductase inhibitors, particularly persistent side effects such as post-finasteride syndrome, and highlights the need for further investigation.

This review discusses the diagnostic criteria and management strategies for Polycystic Ovary Syndrome (PCOS) and highlights the need for comprehensive clinical assessment, but does not report new clinical findings.

This paper suggests that ketoconazole 2% shampoo may enhance finasteride's effectiveness in treating androgenetic alopecia by more completely inhibiting the dihydrotestosterone pathway.

This review describes the roles of 5α-reductase isozymes in prostate development and pathology and reports no new clinical results.

This review discusses the potential benefits of phytochemicals for hair care and emphasizes the need for more robust preclinical and clinical studies, without reporting new clinical results.

This study found that honokiol inhibits enzymes related to testosterone degradation in vitro, suggesting its potential as a lead compound for developing antiaging bioactive ingredients for men.

This study found that while 5α-reductase inhibitors like finasteride had many serious, unresolved adverse drug reactions, some were not listed in the existing product information.

This systematic review found that treatments for sickle cell disease-related priapism are clinically diverse, with etilefrine, pseudoephedrine/etilefrine-5 inhibitors, and finasteride appearing promising, but further research with robust study designs is needed to establish evidence-based practices.

5α-reductase inhibitors may cause persistent sexual dysfunction and depression, needing more research on long-term effects.

This review analyzed clinical trials and guidelines on 5-α-reductase inhibitors (5-ARIs) and found these drugs significantly improve urinary symptoms in BPH and stabilize hair loss in androgenic alopecia, but may cause sexual dysfunction and gynecomastia.

This study found that Procare and Proscar® finasteride tablets were bioequivalent according to Korea Food and Drug Administration guidelines in healthy male subjects.

This meta-analysis found that treating male androgenetic alopecia with 5α-reductase inhibitors increases the risk of sexual dysfunction, with a statistically significant risk for finasteride but not for dutasteride.

In this study, Trapa bispinosa Roxb. pericarp extract demonstrated inhibitory effects on 5α-reductase activity both in vitro using LNCaP cells and in vivo in a mouse model of benign prostatic hyperplasia, suggesting its potential role in managing the condition.

This article reviews ongoing concerns about the safety of 5α-reductase inhibitors like finasteride, highlighting the lack of long-term data on persistent depression and sexual side effects after drug discontinuation; no new clinical results are reported.

In this study, a new Finasteride conjugate showed stronger inhibition of 5α-reductase and similar reduction of prostate hyperplasia in rats compared to Finasteride, with potentially improved toxicity.

This study found that both a proprietary ultrahigh-pressure extract and a hexanic extract of saw palmetto showed comparable inhibition of 5α-reductase, suggesting similar potential for managing symptoms of benign prostatic hyperplasia.

This article discusses post-finasteride syndrome as a distinct syndrome related to prolonged use of 5α-steroid reductase inhibitors, noting persistent side effects even after discontinuation and no new research results are reported.

In this study, 5 mg of finasteride per day significantly improved urinary symptoms and reduced prostate volume in men with benign prostatic hyperplasia, but increased the risk of sexual dysfunction.

This study developed and validated an HPLC method for detecting a novel 5α-reductase inhibitor in human plasma, supporting its pharmacokinetic evaluation at low doses.

In this study, men with AGA who took finasteride 5 mg daily for 24 months showed a significant increase in hair counts compared to those who received a placebo.

This study developed a theoretical model that suggests finasteride may completely inhibit 5AR type 2, but not sufficiently suppress type 1, leading to only partial reduction of dihydrotestosterone at clinical doses.

This review discusses persistent sexual and nonsexual adverse effects of the 5α-reductase inhibitor finasteride in younger men, including erectile dysfunction, low libido, and depression. It reports no new clinical results but emphasizes further research is needed.

This study suggests that Terminalia chebula fruit extract may promote hair growth in androgenetic alopecia by activating specific signaling pathways and inhibiting 5α-reductase, showing effectiveness comparable to finasteride.

This review suggests that finasteride at 1 mg/day reduces PSA levels similarly to 5 mg/day, but differences in prostate dihydrotestosterone levels may affect prostate cancer diagnosis and prevention.

This study suggests that true binary and ternary inclusion complexes were formed between finasteride and 2-hydroxypropyl-ß-cyclodextrin, with or without the addition of specific polymers.